Sanofi (NASDAQ:SNY) Receives $61.50 Average PT from Analysts

Shares of Sanofi (NASDAQ:SNY) have earned a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $61.50.

A number of equities research analysts have commented on SNY shares. Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Finally, Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th.

Sanofi Price Performance

SNY stock opened at $47.89 on Tuesday. The company has a market capitalization of $116.80 billion, a P/E ratio of 13.30, a PEG ratio of 1.19 and a beta of 0.42. The company has a fifty day moving average price of $46.42 and a 200-day moving average price of $47.99. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. Sanofi has a 52-week low of $43.32 and a 52-week high of $55.77.

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently bought and sold shares of the company. Flagship Harbor Advisors LLC acquired a new stake in Sanofi during the 4th quarter worth about $25,000. Financial Consulate Inc. acquired a new position in shares of Sanofi in the 3rd quarter valued at about $26,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at about $29,000. Palisade Asset Management LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at about $30,000. Finally, First Horizon Corp acquired a new stake in Sanofi during the third quarter worth approximately $33,000. Institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.